A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma
Titel:
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma
Auteur:
Davis, Elizabeth J. Chugh, Rashmi Zhao, Lili Lucas, David R. Biermann, J. Sybil Zalupski, Mark M. Feng, Mary Wong, Sandra L. Jacobson, Jon Zyczynski, Laurie Reinke, Denise Metko, Gino Baker, Laurence H. Schuetze, Scott M.